By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Japanese reagent and medical device firm Kyowa Medex today announced regulators in Japan have approved two companion diagnostics for a drug targeting adult T-cell leukemia-lymphoma (ATL).

The Ministry of Health, Labour, and Welfare approved Kyowa's Poteligeo Test IHC and Poteligeo Test FCM for Kyowa Hakko Kirin's Poteligeo (mogamulizumab) injection, a therapeutic antibody that was also approved by MHLW today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.